Biosion's Partner Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052Release time:2025-06-26 11:05:00Nanjing, China, Newark, U.S.A June. 23, 2025-Biosion, a global, clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc.
Newark, DE, U.S. and Nanjing, China, Apr. 27, 2025-Biosion, a global clinical-stage biotechnology company, announced that its partner, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) applicat
NANJING, China and NEWARK, Del., April 11, 2025-Biosion, Inc. , a global, clinical-stage biotechnology company, today announced that preclinical data for BSI-721, a novel antibody-drug conjugate (ADC) targeting CDH17, will be presented at the upcoming American Association for Cancer Research (AAC
The 13th World ADC San Diego 2022 will be held from September 6 to 9. More than 600 ADC experts from around the world will attend the conference. Biosion will present the next-generation ADC development platform designed to identify the optimized antibodies with superior properties for ADCs. In rec
Biosion, Inc. (“Biosion”), a global R&D stage biotechnology company, announced today the upcoming presentations of non-clinical data from its oncology pipeline, including BSI-060T: anti-siglec-15 antibody and BSI-082: anti-SIRP antibody, at the American Association for Cancer Research (AACR) Annual
Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody; Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned upon advancement of PYX-106
This license agreement continues to build on Biosion’s efforts to create and develop meaningful biologics to treat resistant, relapsed and residual disease for patients worldwide.
New funding will strengthen Biosion’s “In Global For Global” positioning by accelerating its clinical pipeline and expanding its global biologics development teams
HAMPTON, N.J., November 12, 2021 — Celldex Therapeutics, Inc. today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster ses
Newark, DE, Nanjing CN – Dec 10, 2020. Biosion Inc. (“Biosion”) today announced completion of ¥200 Million RMB (~$30 Million USD) of financing to transition Biosion into a clinical stage company within twelve months. The financing was led by Lapam Capital, joined by Kaiyuan Capital, Oceanpine Health